End Price Gouging for Medications Act
1/4/2025, 11:17 AMSummary of Bill HR 4215
Bill 118 hr 4215, also known as the End Price Gouging for Medications Act, is a piece of legislation currently being considered by the US Congress. The purpose of this bill is to address the issue of price gouging in the pharmaceutical industry, specifically in relation to medications.The bill aims to prevent pharmaceutical companies from unfairly raising the prices of essential medications, such as insulin and EpiPens, which are necessary for the health and well-being of many Americans. Price gouging occurs when companies significantly increase the price of a product without any justification, often leading to financial hardship for consumers who rely on these medications.
If passed, the End Price Gouging for Medications Act would establish regulations to limit the ability of pharmaceutical companies to engage in price gouging. This could include measures such as price caps, transparency requirements, and penalties for companies found to be engaging in unfair pricing practices. Supporters of the bill argue that it is necessary to protect consumers from the harmful effects of price gouging, which can lead to individuals being unable to afford the medications they need to stay healthy. They believe that the government has a responsibility to intervene in the pharmaceutical industry to ensure that essential medications remain affordable for all Americans. Opponents of the bill may argue that government intervention in pricing could have unintended consequences, such as limiting innovation in the pharmaceutical industry or leading to shortages of essential medications. They may also argue that market forces should be allowed to determine the price of medications, rather than government regulation. Overall, the End Price Gouging for Medications Act is a proposed piece of legislation aimed at addressing the issue of price gouging in the pharmaceutical industry. If passed, it could have significant implications for how medications are priced and accessed by consumers in the United States.
Congressional Summary of HR 4215
End Price Gouging for Medications Act
This bill requires the Department of Health and Human Services (HHS) to set maximum prices for prescription drugs under specified federal health programs. Specifically, HHS must establish reference prices based on certain factors, including the lowest retail price for a drug among specified reference countries.
Retail prices of covered drugs under specified federal health programs (e.g., Medicare and Medicaid) may not exceed the established reference prices. Drugs must also be available at such prices to uninsured individuals and to individuals with private health insurance.
Read the Full Bill
Current Status of Bill HR 4215
Bill HR 4215 is currently in the status of Bill Introduced since June 20, 2023. Bill HR 4215 was introduced during Congress 118 and was introduced to the House on June 20, 2023. Bill HR 4215's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024Bipartisan Support of Bill HR 4215
Total Number of Sponsors
3Democrat Sponsors
3Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 4215
Primary Policy Focus
HealthPotential Impact Areas
AsiaAustraliaCanadaCivil actions and liabilityEuropeFranceGermanyHealth care costs and insuranceHealth care coverage and accessInflation and pricesItalyJapanMedicaidMedical researchMedicareMilitary medicineNetherlandsNorth AmericaOceaniaPrescription drugsRetail and wholesale tradesSpainSwedenSwitzerlandUnited KingdomVeterans' medical careAlternate Title(s) of Bill HR 4215
End Price Gouging for Medications ActEnd Price Gouging for Medications ActTo require the Secretary of Health and Human Services to establish reference prices for prescription drugs for purposes of Federal health programs, and for other purposes.Comments
Most relevant
Sponsors and Cosponsors of HR 4215
Latest Bills
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Review of Final Rule Reclassification of Major Sources as Area Sources Under Section 112 of the Clean Air Act".
Bill HJRES 79April 8, 2025
Medicare Dental, Vision, and Hearing Benefit Act of 2025
Bill HR 2045April 8, 2025
Lactation Spaces for Veteran Moms Act
Bill HR 1646April 8, 2025
DMEPOS Relief Act of 2025
Bill HR 2005April 8, 2025
Physicians for Underserved Areas Act
Bill S 1044April 8, 2025
NICS Data Reporting Act
Bill HR 2267April 8, 2025
Providing for consideration of the joint resolution (S.J. Res. 18) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions"; providing for consideration of the joint resolution (S.J. Res. 28) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications"; providing for consideration of the bill (H.R. 1526) to amend title 28, United States Code, to limit the authority of district courts to provide injunctive relief, and for other purposes; providing for consideration of the bill (H.R. 22) to amend the National Voter Registration Act of 1993 to require proof of United States citizenship to register an individual to vote in elections for Federal office, and for other purposes; and for other purposes.
Bill HRES 294April 8, 2025
Providing for consideration of the joint resolution (H.J. Res. 25) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Internal Revenue Service relating to "Gross Proceeds Reporting by Brokers That Regularly Provide Services Effectuating Digital Asset Sales"; providing for consideration of the bill (H.R. 1156) to amend the CARES Act to extend the statute of limitations for fraud under certain unemployment programs, and for other purposes; providing for consideration of the bill (H.R. 1968) making further continuing appropriations and other extensions for the fiscal year ending September 30, 2025, and for other purposes; and for other purposes.
Bill HRES 211April 8, 2025
SAVE Act
Bill HR 22April 8, 2025
A joint resolution disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions".
Bill SJRES 18April 8, 2025
End Price Gouging for Medications Act
Bill S 2044March 13, 2024